Manjunath R, Graziano R F, Green W R
J Immunol. 1986 Mar 15;136(6):2271-9.
Two variant subclones, called cl.18-5 and cl.18-12, were derived from the AKR.H-2bSL1 tumor cell line that were, in contrast to the parental cells, selectively insusceptible to H-2-restricted anti-AKR/Gross virus cytotoxic T lymphocytes (CTL). Cell surface expression of viral envelope (env) and group-specific antigens (gag) on these CTL-resistant variants were analyzed and compared with the expression of these antigens on AKR.H-2bSL1 and two other CTL-susceptible clones, cl.1 and cl.5, also derived from AKR.H-2bSL1. Although normal levels of gag-encoded and H-2 antigens were displayed on the CTL-resistant variants, the expression of five distinct determinants of viral gp70 antigen as defined by monoclonal antibodies was significantly decreased on these CTL-resistant variants relative to their expression on the CTL-susceptible cell lines. However, similar dramatic changes in cell surface gp70 antigen expression were undetectable as defined by anti-gp70-specific antiserum. Immunoprecipitation and gel electrophoretic analysis revealed that gp70 molecules from cl.18-5 cells had a lower m.w. than those of AKR.H-2bSL1, but there were no differences in the m.w. of gp70 antigens from AKR.H-2bSL1, cl.5, and cl.18-12 cells. Expression of the five gp70 antigenic determinants mentioned above was completely restored by exposure of cl.18-5 and cl.18-12 cells to the halogenated pyrimidine, iododeoxyuridine (IudR). Treatment of cl.18-5 and cl.18-12 cells with IudR simultaneously restored CTL susceptibility of these cells to anti-AKR/Gross virus CTL without affecting gag and H-2 antigen expression. Viral gp70 antigen immunoprecipitated from IudR-treated cl.18-5 cells had a mobility slightly lower, but different from that of untreated cl.18-5 cells. Pulse-labeling with [35S]-methionine showed that IudR treatment of cl.18-5 cells caused the expression of an additional high m.w. gp70 precursor protein originally absent in untreated cl.18-5 cells but present on parental AKR.H-2bSL1 cells. Collectively, these results pointed to the involvement of viral gp70 antigenic determinants in the recognition of AKR/Gross virus-induced tumor targets by anti-AKR/Gross virus CTL.
从AKR.H-2bSL1肿瘤细胞系中衍生出两个变异亚克隆,分别称为cl.18-5和cl.18-12。与亲代细胞不同,它们对H-2限制性抗AKR/格罗斯病毒细胞毒性T淋巴细胞(CTL)具有选择性抗性。分析了这些抗CTL变异体上病毒包膜(env)和群特异性抗原(gag)的细胞表面表达,并与AKR.H-2bSL1以及同样源自AKR.H-2bSL1的另外两个对CTL敏感的克隆cl.1和cl.5上这些抗原的表达进行了比较。尽管抗CTL变异体上显示出正常水平的gag编码抗原和H-2抗原,但相对于它们在对CTL敏感的细胞系上的表达,由单克隆抗体定义的病毒gp70抗原的五个不同决定簇在这些抗CTL变异体上的表达显著降低。然而,用抗gp70特异性抗血清定义时,未检测到细胞表面gp70抗原表达有类似的显著变化。免疫沉淀和凝胶电泳分析表明,cl.18-5细胞的gp70分子的分子量低于AKR.H-2bSL1细胞的gp70分子,但AKR.H-2bSL1、cl.5和cl.18-12细胞的gp70抗原的分子量没有差异。将cl.18-5和cl.18-12细胞暴露于卤代嘧啶碘脱氧尿苷(IudR)后,上述五个gp70抗原决定簇的表达完全恢复。用IudR处理cl.18-5和cl.18-12细胞同时恢复了这些细胞对抗AKR/格罗斯病毒CTL的敏感性,而不影响gag和H-2抗原的表达。从经IudR处理的cl.18-5细胞中免疫沉淀的病毒gp70抗原的迁移率略低,但与未处理的cl.18-5细胞的不同。用[35S]-甲硫氨酸脉冲标记表明,用IudR处理cl.18-5细胞会导致表达一种额外的高分子量gp70前体蛋白,该蛋白在未处理的cl.18-5细胞中原本不存在,但在亲代AKR.H-2bSL1细胞中存在。总的来说,这些结果表明病毒gp70抗原决定簇参与了抗AKR/格罗斯病毒CTL对AKR/格罗斯病毒诱导的肿瘤靶标的识别。